AI assistant
Athira Pharma, Inc. — Director's Dealing 2024
Oct 4, 2024
35038_dirs_2024-10-03_b7053835-f653-47b2-bb18-4fbd23abac9a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2024-10-01
Reporting Person: San Martin Javier (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-10-01 | Restricted Stock Units | $ | A | 140000 | Acquired | Common Stock (140000) | Direct | |
| 2024-10-01 | Stock Option (Right to Buy) | $0.4499 | A | 140000 | Acquired | 2034-09-30 | Common Stock (140000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F2: One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.
F3: One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.